Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Beyond the Headlines: What’s trending in medical news?
Beyond the Endpoint
25 minutes 52 seconds
8 months ago
Beyond the Headlines: What’s trending in medical news?
Ozempic curbing alcohol cravings, ADHD linked to shorter life expectancy, and an NBA rising star diagnosed with DVT—what does the science actually say? In this first episode of Beyond the Headlines, a new Beyond the Endpoint series, hosts Emily O’Brien and Manesh Patel break down the research behind these trending stories.
Access resources related to this episode https://dcri.org/blog/ep-5-beyond-headlines
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
